0000000000246609

AUTHOR

Alicia Serrano

showing 12 related works from this author

Changes in myocardial iron content following administration of intravenous iron (Myocardial‐IRON): Study design

2018

Treatment with intravenous ferric carboxymaltose (FCM) has been shown to improve symptoms, functional capacity, and quality of life in patients with heart failure and iron deficiency. However, the underlying mechanisms for these beneficial effects remain undetermined. The aim of this study is to quantify cardiac magnetic resonance changes in myocardial iron content after administration of intravenous FCM in patients with heart failure and iron deficiency and contrast them with parameters of heart failure severity. This is a multicenter, double-blind, randomized study. Fifty patients with stable symptomatic heart failure, left ventricular ejection fraction <50%, and iron deficiency will be r…

MaleTime FactorsMyocardial ironheart failure030204 cardiovascular system & hematologyFerric CompoundsSeverity of Illness IndexVentricular Function Left030218 nuclear medicine & medical imaginglaw.invention0302 clinical medicineiron deficiencyClinical ProtocolsQuality of lifeRandomized controlled triallawCardiac Magnetic Resonance Ferric Carboxymaltose Heart Failure Iron Deficiency Myocardial IronInfusions IntravenousEjection fractionAnemia Iron-DeficiencyGeneral MedicineIron deficiencyferric carboxymaltoseTreatment OutcomeResearch DesignCardiologyFemaleCardiology and Cardiovascular MedicineCardiac function curvemedicine.medical_specialtyTrial DesignsMagnetic Resonance Imaging CinePlacebocardiac magnetic resonance03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltosemyocardial ironAgedHeart Failurebusiness.industryMyocardiumStroke VolumeRecovery of Functionmedicine.diseaseSpainHeart failureHematinicsQuality of Lifebusiness
researchProduct

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron : The Myocardial- Trial

2020

Background Intravenous ferric carboxymaltose ( FCM ) improves symptoms, functional capacity, and quality of life in heart failure and iron deficiency. The mechanisms underlying these effects are not fully understood. The aim of this study was to examine changes in myocardial iron content after FCM administration in patients with heart failure and iron deficiency using cardiac magnetic resonance. Methods and Results Fifty‐three stable heart failure and iron deficiency patients were randomly assigned 1:1 to receive intravenous FCM or placebo in a multicenter, double‐blind study. T2* and T1 mapping cardiac magnetic resonance sequences, noninvasive surrogates of intramyocardial iron, were eval…

MaleCardiac magnetic resonance*ferric carboxymaltoseMagnetic Resonance Imaging (MRI)Myocardial ironAnèmia*heart failure030204 cardiovascular system & hematologyFerric Compounds0302 clinical medicine030212 general & internal medicineOriginal Researchcardiac magnetic resonance ferric carboxymaltose heart failure iron deficiency myocardial ironAnemia Iron-DeficiencyAnemiaIron deficiencyMiddle AgedMyocardial ironMagnetic Resonance Imaging*myocardial ironMagnetic resonanceCardiologyAdministration IntravenousFemaleCardiology and Cardiovascular Medicine*cardiac magnetic resonancemedicine.medical_specialtyNoninvasive imagingCardiomyopathyIronIntravenous ironHeart failureFERRIC CARBOXYMALTOSE03 medical and health sciencesDouble-Blind MethodInternal medicinemedicineHumansMaltoseAgedPharmacologybusiness.industryMyocardiumIron deficiencyRessonància magnèticaMiocardimedicine.diseaseFerric carboxymaltoseTreatmentHeart failureHematinicsbusinessCardiac magnetic resonance*iron deficiencyFerro
researchProduct

Ighv Mutational Status By Deep Next Generation Sequencing Refines Ighv Sanger Sequencing Classification in Patients with Chronic Lymphocytic Leukaemia

2019

Introduction: Determination of the mutational status of rearranged immunoglobulin heavy chain variable (IgHV) genes in patients with Chronic Lymphocytic Leukaemia (CLL), is considered one of the most important prognostic factors: patients with unmutated IgHV (UM; ≥98% of identity to the germline) genes have a more aggressive disease course and develop more frequently unfavourable genetic deletions or mutations than patients with mutated IgHV (M; ≤98%). Mutational status, is currently determined by Sanger sequencing (Sseq) that allows the analysis of the major clone, however, international guidelines recommend caution in assigning mutational status in cases with "Borderline" IgHV identity (9…

Sanger sequencingGeneticsclone (Java method)ImmunologyLocus (genetics)Cell BiologyHematologyBiologyBiochemistryDNA sequencinglaw.inventionsymbols.namesakelawsymbolsMutation testingMultiplexIGHV@Polymerase chain reactionBlood
researchProduct

Assessing the potential association between SARS-CoV-2 RNA load in the respiratory tract and COVID-19 mortality.

2020

Special Issue on New coronavirus (2019‐nCoV or SARS‐CoV‐2) and the outbreak of the respiratory illness (COVID‐19): Part‐XI

Male2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory System03 medical and health sciences0302 clinical medicineVirologyInternal medicineMedicineHumans030212 general & internal medicineAgedbusiness.industrySARS-CoV-2RNACOVID-19Middle AgedViral LoadVirologyInfectious Diseasesmedicine.anatomical_structureHospital admissionRNA Viral030211 gastroenterology & hepatologyFemalebusinessBiomarkersRespiratory tractJournal of medical virology
researchProduct

Easy One-Step Amplification and Labeling Procedure for Copy Number Variation Detection.

2019

Abstract Background The specific characteristics of copy number variations (CNVs) require specific methods of detection and characterization. We developed the Easy One-Step Amplification and Labeling procedure for CNV detection (EOSAL-CNV), a new method based on proportional amplification and labeling of amplicons in 1 PCR. Methods We used tailed primers for specific amplification and a pair of labeling probes (only 1 labeled) for amplification and labeling of all amplicons in just 1 reaction. Products were loaded directly onto a capillary DNA sequencer for fragment sizing and quantification. Data obtained could be analyzed by Microsoft Excel spreadsheet or EOSAL-CNV analysis software. We d…

0301 basic medicineDNA Copy Number VariationsClinical BiochemistryComputational biologyPolymerase Chain Reaction03 medical and health sciences0302 clinical medicineHumansMultiplexMultiplex ligation-dependent probe amplificationCopy-number variationIn Situ Hybridization FluorescenceFluorescent DyesChemistryBiochemistry (medical)Sequence Analysis DNAAmpliconChromosome 17 (human)MSH6DNA sequencer030104 developmental biologyReceptors LDLMSH2030220 oncology & carcinogenesisDNA ProbesMultiplex Polymerase Chain ReactionClinical chemistry
researchProduct

Detection of Immunoglobulin Heavy Chain Gene Clonality By High-Throughput Sequencing for Minimal Residual Disease Monitoring in Chronic Lymphocytic L…

2019

Introduction: The negative minimal residual disease (MRD) after treatment has been recently accepted as endpoint for Chronic Lymphocytic Leukaemia (CLL) clinical trials. Conventionally, MRD can be detected by using multi-color Flow Cytometry (FC) with high sensitivity. Determination of the clonal immunoglobulin gene rearrangement can be a useful monitoring marker in a broad range of B-cell lymphoproliferative neoplasms. Moreover, the mutational status of immunoglobulin heavy chain variable (IgHV) rearrangement is considered one of the most important prognostic factors in CLL. Therefore, the identification of the IgHV rearrangement can be a useful marker both at diagnostic and as monitoring …

clone (Java method)Chronic lymphocytic leukemiaImmunologyCell BiologyHematologyComputational biologyBiologymedicine.diseaseBiochemistryMinimal residual diseasegenomic DNAEuroFlowhemic and lymphatic diseasesAcute lymphocytic leukemiamedicineMultiplexIGHV@Blood
researchProduct

Therapy-related acute myeloid leukemia developing 14 years after allogeneic hematopoietic stem cell transplantation, from a persistent R882H- DNMT3A …

2018

Abstract Background Therapy-related acute myeloid leukemia (t-AML) develops in patients with prior exposure to cytotoxic therapies. Selection of a pre-existing TP53 mutated clone prone to acquire additional mutational events has been suggested as the main pathogenic mechanism of t-AML. Here, we report a unique case of t-AML which developed from a pre-existing DNMT3A mutated clone that persisted in the patient for more than 10 years despite treatment with intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (alloHSCT). Case presentation A 42-year-old male was diagnosed with AML harboring a normal karyotype and mutations in the NPM1 (c.863_864ins, p.W288 fs*12), DNMT3…

AdultMaleOncologymedicine.medical_specialtyNPM1Allogeneic transplantationmedicine.medical_treatmentClinical BiochemistryMutation MissenseClone (cell biology)Therapy-Related Acute Myeloid LeukemiaHematopoietic stem cell transplantationDNA Methyltransferase 3APathology and Forensic Medicine03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansTransplantation HomologousDNA (Cytosine-5-)-MethyltransferasesMolecular BiologyBone Marrow Transplantationbusiness.industryMyeloid leukemiaInduction chemotherapyTransplantationLeukemia Myeloid Acute030220 oncology & carcinogenesisbusinessNucleophosmin030215 immunologyExperimental and Molecular Pathology
researchProduct

Epidemiological Characterization and Determination of TP53 and IGHV Mutational Status of a Large Series of Previously-Untreated Chronic Lymphocytic L…

2021

Abstract Introduction: Among the genetic lesions described in chronic lymphocytic leukemia (CLL), TP53 and IGHV mutational status are well-established prognostic biomarkers. While mutations resulting in dysregulation of TP53 are associated with chemo-resistance, mutated IGHV (IGHV-M) identifies a good prognosis and unmutated (IGHV-UM) is associated with an aggressive clinical outcome. Thus, molecular assessment of TP53 and IGHV mutational status is recommended to make treatment decisions. Moreover, 30% of CLL patients have a highly homologous complementarity-determining region 3 (CDR3), allowing their classification in subsets based on the stereotypical B-cell receptor immunoglobulins (BcR …

medicine.medical_specialtybusiness.industryImmunologyLarge seriesCell BiologyHematologyBiochemistryEpidemiologyImmunologymedicineMutational statusIGHV@businessUntreated Chronic Lymphocytic LeukemiaBlood
researchProduct

Liquid Biopsy and Lymphoma Monitoring in Clinical Practice

2021

Abstract INTRODUCTION Lymphomas represent the fourth most frequent type of cancer, 90% of them arising from B cell lymphocytes. Despite their high prevalence, around 40% remain incurable because of refractoriness to current chemoimmunotherapy or disease relapse after obtaining response (Li et al., 2018; Meng et al., 2020). The cell of origin is a B lymphocyte with a unique B cell receptor (BCR). The BCR is an immunoglobulin composed of two heavy chains (IgH) and two light chains (IgL) whose genes have multiple coding segments that through rearrangement first and further somatic hypermutation in the germinal center, generate a unique sequence that could be used to monitor the treatment respo…

Clinical Practicemedicine.medical_specialtybusiness.industryImmunologymedicineCell BiologyHematologyRadiologyLiquid biopsybusinessmedicine.diseaseBiochemistryLymphomaBlood
researchProduct

Impact of Clinical Features, Cytogenetics, Genetic Mutations and Methylation of CDKN2B and DLC-1 Promoters on Treatment Response to Azacitidine

2019

Introduction : Azacitidine (AZA) is a DNA hypomethylating agent used in myeloid neoplasms, however approximately half of patients show treatment failure or relapse. Last years, several studies have showed that genetic mutations may influence on response and survival of the treated patients. Other biomarkers that have traditionally been associated with the response to AZA are the recovery of the platelet count and the presence of abnormalities in the chromosome 7. Finally, the methylation dynamics of genes promoters could be a useful tool to predict the clinical response. Aim: To assess the predictive value on response to AZA of clinical features, cytogenetics, genetic mutations and the meth…

Mutationmedicine.medical_specialtyImmunologyAzacitidineCytogeneticsPromoterCell BiologyHematologyMethylationBiologymedicine.diseasemedicine.disease_causeBiochemistrychemistry.chemical_compoundchemistryCDKN2BChromosome abnormalitymedicineCancer researchDNAmedicine.drugBlood
researchProduct

Amplification of human β-glucoronidase gene for appraising the accuracy of negative SARS-CoV-2 RT-PCR results in upper respiratory tract specimens

2020

Real-time reverse transcription polymerase-chain reaction (RT-PCR) is the mainstay of Covid-19 diagnosis. False-negative RT-PCR results may hamper clinical management of patients and hinder the adoption of epidemiological measures to control the pandemic. The current study was aimed at assessing whether amplification of β-glucoronidase (GUSB) gene would help estimate the accuracy of SARS-CoV-2 RT-PCR negative results in upper respiratory tract (URT) specimens. URT specimens that tested negative by SARS-CoV-2 RT-PCR displayed higher GUSB RT-PCR cycle thresholds (CT) (P=0.070) than those testing positive (median, 30.7; range, 27.0-40.0, and median 29.7; range 25.5-36.8, respectively), this re…

AdultMalemedicine.medical_specialtyAdolescentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Respiratory SystemSensitivity and SpecificityGastroenterologyYoung Adult03 medical and health sciences0302 clinical medicineVirologyInternal medicinemedicineHumansIn patient030212 general & internal medicineRespiratory systemChildLetter to the EditorGeneAgedGlucuronidaseAged 80 and overReceiver operating characteristicClinical Laboratory TechniquesReverse Transcriptase Polymerase Chain ReactionSARS-CoV-2business.industryCurve analysisCOVID-19Middle AgedVirologyReverse transcriptaseGlucuronidaseTrue negativeInfectious Diseasesmedicine.anatomical_structureReal-time polymerase chain reactionChild PreschoolRNA ViralFemale030211 gastroenterology & hepatologybusinessRespiratory tract
researchProduct

Prognostic Value of Radiomics Signature By Diagnostic 18F-FDG PET/CT Analysis in Aggressive Non-Hodgkin's Lymphoma

2018

Abstract BACKGROUND Although the overall prognosis of patients with aggressive non-Hodgkin's lymphoma (NHL) has improved, nearly a third of patients will have refractory disease or relapse. Identification of these high-risk patients using traditional prognostic factors is limited. PET is the recommended imaging modality for the staging of FDG-avid lymphoma but the value of a comprehensive new imaging biomarkers analysis applied to PET for the prediction of patients outcome has still not been deeply investigated. New metrics estimating the overall tumor burden such as metabolic tumor volume (MTV) and those that may capture intratumoral biological heterogeneity such as total lesion glycolysis…

medicine.medical_specialtybusiness.industryImmunologyCell BiologyHematologyMetabolic tumor volumemedicine.diseaseLinear discriminant analysisBiochemistryLymphomaNon-Hodgkin's lymphomaCorrelationRadiomicsKurtosisMedicineFdg pet ctRadiologybusinessBlood
researchProduct